Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.

Pyoderma gangrenosum-a novel approach? Wien Med Wochenschr (2016) 1.08

Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm (2014) 1.07

The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clin Rheumatol (2014) 0.93

Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient. Paediatr Drugs (2017) 0.91

Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol (2014) 0.91

Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol (2013) 0.91

Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm (2015) 0.89

Untangling the web of systemic autoinflammatory diseases. Mediators Inflamm (2014) 0.85

Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open (2015) 0.84

Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. Clin Rheumatol (2014) 0.83

Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int (2015) 0.81

Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. Mediators Inflamm (2015) 0.80

Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol (2014) 0.79

Successful treatment with adalimumab for severe multifocal choroiditis and panuveitis in presumed (early-onset) ocular sarcoidosis. Int Ophthalmol (2015) 0.79

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis (2016) 0.77

The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review. Cardiol Res Pract (2016) 0.76

Lung Involvement in Children with Hereditary Autoinflammatory Disorders. Int J Mol Sci (2016) 0.75

Human RELA haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration. J Exp Med (2017) 0.75

Lights and shadows in autoinflammatory syndromes from the childhood and adulthood perspective. Clin Rheumatol (2015) 0.75

The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. Clin Rheumatol (2015) 0.75

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17

Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum (1997) 6.04

Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet (2004) 4.23

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86

Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum (2007) 3.65

An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med (2009) 3.56

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36

Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med (2007) 3.18

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71

The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A (2006) 2.59

Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther (2002) 2.58

Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford) (2006) 2.57

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34

Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A (2003) 2.30

Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med (1986) 2.29

Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr (1989) 2.25

Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet (2005) 2.24

Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol (2010) 2.17

The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) (2002) 2.10

Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A (2008) 2.06

Colchicine for familial Mediterranean fever. N Engl J Med (1972) 1.95

Familial granulomatous arthritis, iritis, and rash. J Pediatr (1985) 1.90

The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum (2009) 1.87

Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) (2012) 1.78

Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) (2008) 1.74

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.69

The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2002) 1.67

NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum (2007) 1.60

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis (2012) 1.59

Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation. Ophthalmology (2003) 1.56

Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics (1993) 1.49

Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) (2005) 1.48

Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol (2009) 1.46

The syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia. Report of a new family and a review. Eur J Pediatr (2001) 1.46

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum (2008) 1.46

Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics (2011) 1.41

A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc (1997) 1.40

Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood (1995) 1.37

Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant (2008) 1.37

Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) (2005) 1.26

Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis (2006) 1.26

A splice site mutation confirms the role of LPIN2 in Majeed syndrome. Arthritis Rheum (2007) 1.26

Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol (2009) 1.26

Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum (2011) 1.25

Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol (2006) 1.23

Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther (2004) 1.23

The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol (2002) 1.18

Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis (2012) 1.17

Familial Mediterranean fever. Pediatr Nephrol (2003) 1.16

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis (2011) 1.15

Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant (2011) 1.13

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol (2006) 1.12

Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum (2012) 1.10

Treatment of familial Mediterranean fever with anakinra. Ann Intern Med (2007) 1.09

Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun (2004) 1.09

On mice and men: An autosomal recessive syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia. J Pediatr (2000) 1.08

Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr (2010) 1.07

Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum (2011) 1.06

Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med (2012) 1.06

Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol (2006) 1.06

A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum (2011) 1.04

On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis (2011) 1.04

Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes. Arthritis Rheum (2011) 1.03

Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol (1994) 1.03

Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2009) 1.02

Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy (2005) 1.02

Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum (2013) 1.01

Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS). Rheumatology (Oxford) (2005) 1.01

Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum (2003) 1.01

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther (2011) 1.00

Role of interleukin-1β in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. Arthritis Rheum (2011) 1.00

Blau syndrome, clinical and genetic aspects. Autoimmun Rev (2012) 0.99

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis (2010) 0.99

Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum (2011) 0.99

Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol (2007) 0.98

Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol (2009) 0.98

Variable expression and treatment of PAPA syndrome. Ann Rheum Dis (2011) 0.97

Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum (2011) 0.97

Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein. Ann Rheum Dis (2009) 0.96

The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum (2011) 0.96

Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases. Int J Clin Pract (2005) 0.96

Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol (2005) 0.95

Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis (2008) 0.95

Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol (2013) 0.95

Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol (2012) 0.95

Auto inflammatory syndromes: Diagnosis and treatment. Joint Bone Spine (2007) 0.95

Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol (2010) 0.95

Amyloidosis in autoinflammatory syndromes. Autoimmun Rev (2012) 0.95

Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun Rev (2008) 0.94

Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. Am J Med Genet A (2006) 0.94

Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr Dermatol (2012) 0.93

Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS (2006) 0.93

Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) (2007) 0.93

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther (2011) 0.92

Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol (2013) 0.92

Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol (2012) 0.92

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96

EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis (2010) 3.47

Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11

Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol (2011) 2.45

Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol (2010) 2.17

Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series. Clin Exp Rheumatol (2013) 2.09

Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis (2013) 2.09

Autophagy in human health and disease. N Engl J Med (2013) 2.04

Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum (2010) 1.97

Mevalonate kinase genotype in children with recurrent fevers and high serum IgD level. Rheumatol Int (2012) 1.95

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89

Gout: why is this curable disease so seldom cured? Ann Rheum Dis (2012) 1.84

Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child (2010) 1.61

Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum (2004) 1.59

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis (2012) 1.59

The role of US examination in the management of acute abdomen. Crit Ultrasound J (2013) 1.58

Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47

Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood (2010) 1.43

Guillain-Barré syndrome following adalimumab treatment. Clin Exp Rheumatol (2012) 1.41

The enigma of periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome. Pediatr Infect Dis J (2014) 1.39

Phytothermotherapy in osteoarthritis: a randomized controlled clinical trial. J Altern Complement Med (2011) 1.38

miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol (2009) 1.34

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) (2013) 1.29

Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications. Basic Res Cardiol (2007) 1.26

Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep (2013) 1.25

Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev (2005) 1.25

Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21

Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics (2008) 1.20

Differences in perfusion CT parameter values with commercial software upgrades: a preliminary report about algorithm consistency and stability. Acta Radiol (2013) 1.20

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16

Resistant Behçet disease responsive to anakinra. Ann Intern Med (2008) 1.15

OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol (2011) 1.14

Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatol Int (2010) 1.14

The systemic-onset variant of juvenile idiopathic arthritis needs to be recorded as an autoinflammatory syndrome: comment on the review by Nigrovic. Arthritis Rheumatol (2014) 1.12

Efficacy of anakinra in refractory Behçet's disease sacroiliitis. Clin Exp Rheumatol (2014) 1.12

Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev (2007) 1.11

p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells. Blood (2007) 1.09

Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta (2012) 1.09

Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes. J Cell Biochem (2009) 1.09

Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr (2010) 1.07

Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol (2010) 1.06

Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05

Penile involvement in Henoch-Schönlein purpura with good prognosis. Scand J Urol Nephrol (2007) 1.05

Specific recycling receptors are targeted to the immune synapse by the intraflagellar transport system. J Cell Sci (2014) 1.05

Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum (2004) 1.04

Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev (2012) 1.03

The role of infection in Kawasaki syndrome. J Infect (2013) 1.03

Computed tomographic evaluation of mesentery: diagnostic value in acute mesenteric ischemia. J Comput Assist Tomogr (2012) 1.03

Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J (2011) 1.03

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord (2014) 1.03

A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography. Ann Rheum Dis (2007) 1.02

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol (2012) 1.02

Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol (2011) 1.02

Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine (2010) 1.02

Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS One (2013) 1.01

Debate around infection-dependent hemophagocytic syndrome in paediatrics. BMC Infect Dis (2013) 1.01

Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics (2003) 1.00

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol (2008) 1.00

Blau syndrome, clinical and genetic aspects. Autoimmun Rev (2012) 0.99

Sigmoid diverticulitis: US findings. Crit Ultrasound J (2013) 0.99

The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. Int J Rheum Dis (2013) 0.98

Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol (2010) 0.98

Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol (2012) 0.98

Dermatomyositis and malignancy of the pharynx in Caucasian patients: report of two observations. Rheumatol Int (2003) 0.97

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol (2010) 0.97

Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int (2009) 0.95

International position paper on febuxostat. Clin Rheumatol (2010) 0.95

Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol (2012) 0.95

International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatology (Oxford) (2014) 0.95

Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol (2014) 0.94

Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol (2013) 0.94